Related to FDA Clears Fifth Indication for Lilly's Cymbalta as Treatment for Musculoskeletal Pain

• Roche’s Cobas Test for Chlamydia and Gonorrhea Granted 510(k) Clearance in U.S.
  
• FDA Okays Shire's ADHD Drug Vyvanse for Maintenance Therapy in Adults
  
• FDA Issues Draft Guidance for Getting Biosimilars Approved
  
• FDA Clears Gen-Probe’s PCA3 Urine Assay for Predicting Need for Repeat Prostate Biopsies
  
• Scientists Say Anticancer Drug Imatinib Can Stop Morphine Tolerance
  
• BioSante, Teva Win FDA Nod for Male Hypogonadism Therapy
  
• Omeros Wins $1.04M NIDA Grant to Progress NMUR2 Inhibitor Analgesics
  
• FDA Clears MedImmune’s FluMist Quadrivalent Flu Vaccine
  
• Fast Forward to Provide Funding for Concert’s MS Spasticity and Pain Candidate
  
• FDA Clears Discovery Laboratories’ Drug for Respiratory Distress Syndrome in Infants
  
• FDA Approves Organogenesis’ Gintuit Cell-Based Product for Gum Disease
  
• Amylin, Lilly Confirm EU Approval of Byetta as Adjunct to Insulin for Type 2 Diabetes
  
• FDA Clears Affymax and Takeda’s Once-Monthly ESA for Anemic CKD Patients on Dialysis
  
• 2-to-1 Majority of Respondents to a GEN Poll See Smooth Sailing Ahead for Vivus' Obesity Therapy
  
• Lawmaker Criticizes Continued Development of Pure-Hydrocodone Drugs
  
• FDA Clears Avid’s Amyloid Plaque Imaging Agent for Aiding Alzheimer Disease Diagnosis
  
• FDA Clears Qiagen’s Rotor-Gene MDx RT-PCR IVD Platform and Influenza Assay
  
• FDA Clears Leica’s Her2 Immunohistochemical Assay on Bond-Max Instrument
  
• Takeda’s Type 2 Diabetes Therapies Set Back Again by FDA
  
• FDA Requests More Risk-Benefit Data for Amgen’s Xgeva sBLA in Prostate Cancer